Table 3.

Incidence and risk of end-stage renal disease in patients with Crohn’s disease and ulcerative colitis

	Total No. (n)	ESRD cases (n)	Person-years	ESRD incidence (per 1000 person-years)	Crude HR (95%CI)	P value	Model 11 HR (95%CI)	P value	Model 22 HR (95%CI)	P value	Model 33 HR (95%CI)	P value
Total CD						< 0.001		< 0.001		< 0.001		< 0.001
Non-CD control	37755	24	184988	0.13	1 (reference)		1 (reference)		1 (reference)		1 (reference)
CD cohort	12585	31	61189	0.51	3.90 (2.29-6.65)		4.00 (2.35-6.82)		3.98 (2.31-6.85)		6.33 (2.75-14.56)
CD subgroup						< 0.001		< 0.001		< 0.001		< 0.001
Non-CD control	37755	24	184988	0.13	1 (reference)		1 (reference)		1 (reference)		1 (reference)
Incident CD group	5586	14	21836	0.64	4.92 (2.53-9.57)		5.18 (2.66-10.07)		4.21 (2.12-8.35)		6.30 (2.56-15.26)
Prevalent CD group	6999	17	39353	0.43	3.34 (1.79-6.23)		3.37(1.81-6.29)		3.81(2.03-7.16)		6.38 (2.47-16.47)
Total UC						0.941		0.961		0.307		0.089
Non-UC control	78681	142	383587	0.37	1 (reference)		1 (reference)		1 (reference)		1 (reference)
UC cohort	26227	48	128056	0.37	1.01 (0.73-1.40)		1.01 (0.73-1.40)		1.22 (0.88-1.70)		2.01 (0.90-4.51)
UC subgroup						0.821		0.821		0.513		0.235
Non-UC control	78681	142	383587	0.37	1 (reference)		1 (reference)		1 (reference)		1 (reference)
Incident UC group	11020	18	43810	0.41	1.14 (0.70-1.87)		1.27 (0.77-2.08)		1.19 (0.73-1.96)		1.99 (0.83-4.80)
Prevalent UC group	15207	30	84247	0.36	0.95 (0.64-1.41)		0.90 (0.61-1.33)		1.24 (0.83-1.84)		2.03 (0.87-4.72)

¹Model 1: adjusted for age and sex;

²Model 2: adjusted for model 1 + region, income, diabetes mellitus, hypertension, dyslipidemia, congestive heart failure, ischemic heart disease, gout and/or hyperuricemia;

³Model 3: adjusted for model 2 + medication use (5-aminosalicylic acid, corticosteroids, immunomodulators, and anti-tumor necrosis factor -α agents). CD: Crohn’s disease; CI: Confidence interval; ESRD: End-stage renal disease; HR: Hazard ratio; No: Number; UC: Ulcerative colitis.